These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8856204)

  • 1. Will pimagidine improve survival of diabetics on dialysis?
    Friedman EA
    Nephrol Dial Transplant; 1996 Aug; 11(8):1524-7. PubMed ID: 8856204
    [No Abstract]   [Full Text] [Related]  

  • 2. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications.
    Friedman EA
    Diabetes Care; 1999 Mar; 22 Suppl 2():B65-71. PubMed ID: 10097902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Accumulation of AGE (advanced glycosylation end-products) in the aging process, in diabetes mellitus and in chronic renal failure].
    Wisotzky J; Sommer M; Schubert K; Stein G
    Med Klin (Munich); 1996 Jul; 91(7):454-7. PubMed ID: 8756114
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimizing end-stage renal disease therapy for the patient with diabetes mellitus.
    Friedlander MA; Hricik DE
    Semin Nephrol; 1997 Jul; 17(4):331-45. PubMed ID: 9241718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of glucose levels on advanced glycation end products in hemodialysis.
    Godfrey AR
    Hemodial Int; 2007 Jul; 11(3):278-85. PubMed ID: 17576290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced glycation end products in renal failure: an overview.
    Noordzij MJ; Lefrandt JD; Smit AJ
    J Ren Care; 2008 Dec; 34(4):207-12. PubMed ID: 19090900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of advanced glycosylation end products in the pathogenesis of hypertension].
    Zukowska-Szczechowska E; Tomaszewski M; Grzeszczak W
    Przegl Lek; 2003; 60(9):585-7. PubMed ID: 15065338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advanced glycosylation end products or glycotoxins: under-evaluated components of diet?].
    Wautier JL
    Rev Prat; 2001 Sep; 51(13):1397-9. PubMed ID: 11601066
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pre-occupying increase in diabetes as cause for terminal kidney failure. Evaluation of treatment strategies].
    Pérez García R; Rodríguez Benítez P; Dall'Anesse C; Gómez Campderá F; Valderrábano F
    An Med Interna; 2001 Apr; 18(4):175-80. PubMed ID: 11496535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of advanced glycation end-products in the development of atherosclerosis.
    Odetti P
    Ital Heart J; 2001 Sep; 2 Suppl 3():34S-36S. PubMed ID: 11593929
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term survival with peritoneal dialysis in ESRD due to diabetes.
    Passadakis P; Thodis E; Vargemezis V; Oreopoulos D
    Clin Nephrol; 2001 Oct; 56(4):257-70. PubMed ID: 11680655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Targeted AGEes and AGEs cross-link in drug discovery: preventing and reversing arterial sclerosis in aging and diabetes].
    Zhong W; Wang LL; Cui H; Li S
    Yao Xue Xue Bao; 2005 Jan; 40(1):91-6. PubMed ID: 15881334
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes.
    Gardiner TA; Anderson HR; Stitt AW
    J Pathol; 2003 Oct; 201(2):328-33. PubMed ID: 14517851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis.
    Meerwaldt R; Zeebregts CJ; Navis G; Hillebrands JL; Lefrandt JD; Smit AJ
    Am J Kidney Dis; 2009 Jan; 53(1):138-50. PubMed ID: 19036487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G6PD deficiency: its role in the high prevalence of hypertension and diabetes mellitus.
    Gaskin RS; Estwick D; Peddi R
    Ethn Dis; 2001; 11(4):749-54. PubMed ID: 11763298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation--are they inter-related?
    Sebeková K; Podracká L; Heidland A; Schinzel R
    Clin Nephrol; 2001 Dec; 56(6):S21-6. PubMed ID: 11770807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression of receptor for advanced glycosylation end products and its modulation by aminoguanidine in diabetic kidney tissue.
    Huang Y; Lin S; Zhou J
    Chin Med J (Engl); 1998 Aug; 111(8):698-704. PubMed ID: 11245022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Survival analysis of diabetic patients on dialysis in Guadeloupe].
    Foucan L; Mérault H; Deloumeaux J; Ekouévi DK; Kangambéga P; Messerchmitt C; Gabriel JM
    Diabetes Metab; 2000 Sep; 26(4):307-13. PubMed ID: 11011224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucotoxicity in peritoneal dialysis--solutions for the solution!
    Holmes CJ
    Adv Chronic Kidney Dis; 2007 Jul; 14(3):269-78. PubMed ID: 17603981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design.
    Khalifah RG; Chen Y; Wassenberg JJ
    Ann N Y Acad Sci; 2005 Jun; 1043():793-806. PubMed ID: 16037307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.